B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy

Timothy J. Roth, Yuri Sheinin, Christine M. Lohse, Susan M. Kuntz, Xavier Frigola, Brant A. Inman, Amy E. Krambeck, Maureen E. Mckenney, Robert Jeffrey Karnes, Michael L. Blute, John C. Cheville, Thomas J. Sebo, Eugene D Kwon

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

B7 coregulatory ligands can be aberrantly expressed in human disease. In the context of cancer, these ligands may act as antigen-specific inhibitors of T-cell-mediated antitumoral immunity. We recently reported that B7-H1 expression by carcinomas of the kidney and bladder portends aggressive disease and diminished survival. The expression of these proteins in prostate cancer, however, has not been investigated. We evaluated B7-H3 and B7-H1 protein expression in the pathologic specimens of 338 men treated for clinically localized prostate cancer between 1995 and 1998 with radical retropubic prostatectomy. Expression levels of B7-H3 in prostate cancer were correlated with pathologic indicators of aggressive cancer as well as clinical outcome. We report that B7-H3 is uniformly and aberrantly expressed by adenocarcinomas of the prostate, high-grade prostatic intraepithelial neoplasia, and four prostate cancer cell lines, whereas B7-H1 is rarely expressed. B7-H3 is expressed by benign prostatic epithelia, although at a more reduced level relative to neoplastic tissue. Increasing levels of B7-H3 intensity correlate with worsening clinicopathologic features of prostate cancer. Marked B7-H3 intensity, present in 67 (19.8%) specimens, confers a >4-fold increased riskof cancer progression after surgery (riskratio , 4.42; P < 0.001). A survey of normal tissues revealed that B7-H3 is expressed within the liver, urothelium, and fetal kidney. In summary, B7-H3 is aberrantly expressed in all prostate cancers and represents an independent predictor of cancer progression following surgery. Moreover, B7-H3 encompasses a novel diagnostic and potential therapeutic target for the clinical management of prostate cancer and, perhaps, other malignancies as well.

Original languageEnglish (US)
Pages (from-to)7893-7900
Number of pages8
JournalCancer Research
Volume67
Issue number16
DOIs
StatePublished - Aug 15 2007

Fingerprint

Prostatic Neoplasms
Ligands
Neoplasms
Therapeutics
Prostatic Intraepithelial Neoplasia
Kidney
Urothelium
Prostatectomy
Cellular Immunity
Prostate
Urinary Bladder
Proteins
Adenocarcinoma
Epithelium
Carcinoma
T-Lymphocytes
Antigens
Cell Line
Survival
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

B7-H3 ligand expression by prostate cancer : A novel marker of prognosis and potential target for therapy. / Roth, Timothy J.; Sheinin, Yuri; Lohse, Christine M.; Kuntz, Susan M.; Frigola, Xavier; Inman, Brant A.; Krambeck, Amy E.; Mckenney, Maureen E.; Karnes, Robert Jeffrey; Blute, Michael L.; Cheville, John C.; Sebo, Thomas J.; Kwon, Eugene D.

In: Cancer Research, Vol. 67, No. 16, 15.08.2007, p. 7893-7900.

Research output: Contribution to journalArticle

Roth, TJ, Sheinin, Y, Lohse, CM, Kuntz, SM, Frigola, X, Inman, BA, Krambeck, AE, Mckenney, ME, Karnes, RJ, Blute, ML, Cheville, JC, Sebo, TJ & Kwon, ED 2007, 'B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy', Cancer Research, vol. 67, no. 16, pp. 7893-7900. https://doi.org/10.1158/0008-5472.CAN-07-1068
Roth, Timothy J. ; Sheinin, Yuri ; Lohse, Christine M. ; Kuntz, Susan M. ; Frigola, Xavier ; Inman, Brant A. ; Krambeck, Amy E. ; Mckenney, Maureen E. ; Karnes, Robert Jeffrey ; Blute, Michael L. ; Cheville, John C. ; Sebo, Thomas J. ; Kwon, Eugene D. / B7-H3 ligand expression by prostate cancer : A novel marker of prognosis and potential target for therapy. In: Cancer Research. 2007 ; Vol. 67, No. 16. pp. 7893-7900.
@article{18578098a48b4388ae14048b16f0f9c0,
title = "B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy",
abstract = "B7 coregulatory ligands can be aberrantly expressed in human disease. In the context of cancer, these ligands may act as antigen-specific inhibitors of T-cell-mediated antitumoral immunity. We recently reported that B7-H1 expression by carcinomas of the kidney and bladder portends aggressive disease and diminished survival. The expression of these proteins in prostate cancer, however, has not been investigated. We evaluated B7-H3 and B7-H1 protein expression in the pathologic specimens of 338 men treated for clinically localized prostate cancer between 1995 and 1998 with radical retropubic prostatectomy. Expression levels of B7-H3 in prostate cancer were correlated with pathologic indicators of aggressive cancer as well as clinical outcome. We report that B7-H3 is uniformly and aberrantly expressed by adenocarcinomas of the prostate, high-grade prostatic intraepithelial neoplasia, and four prostate cancer cell lines, whereas B7-H1 is rarely expressed. B7-H3 is expressed by benign prostatic epithelia, although at a more reduced level relative to neoplastic tissue. Increasing levels of B7-H3 intensity correlate with worsening clinicopathologic features of prostate cancer. Marked B7-H3 intensity, present in 67 (19.8{\%}) specimens, confers a >4-fold increased riskof cancer progression after surgery (riskratio , 4.42; P < 0.001). A survey of normal tissues revealed that B7-H3 is expressed within the liver, urothelium, and fetal kidney. In summary, B7-H3 is aberrantly expressed in all prostate cancers and represents an independent predictor of cancer progression following surgery. Moreover, B7-H3 encompasses a novel diagnostic and potential therapeutic target for the clinical management of prostate cancer and, perhaps, other malignancies as well.",
author = "Roth, {Timothy J.} and Yuri Sheinin and Lohse, {Christine M.} and Kuntz, {Susan M.} and Xavier Frigola and Inman, {Brant A.} and Krambeck, {Amy E.} and Mckenney, {Maureen E.} and Karnes, {Robert Jeffrey} and Blute, {Michael L.} and Cheville, {John C.} and Sebo, {Thomas J.} and Kwon, {Eugene D}",
year = "2007",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-07-1068",
language = "English (US)",
volume = "67",
pages = "7893--7900",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - B7-H3 ligand expression by prostate cancer

T2 - A novel marker of prognosis and potential target for therapy

AU - Roth, Timothy J.

AU - Sheinin, Yuri

AU - Lohse, Christine M.

AU - Kuntz, Susan M.

AU - Frigola, Xavier

AU - Inman, Brant A.

AU - Krambeck, Amy E.

AU - Mckenney, Maureen E.

AU - Karnes, Robert Jeffrey

AU - Blute, Michael L.

AU - Cheville, John C.

AU - Sebo, Thomas J.

AU - Kwon, Eugene D

PY - 2007/8/15

Y1 - 2007/8/15

N2 - B7 coregulatory ligands can be aberrantly expressed in human disease. In the context of cancer, these ligands may act as antigen-specific inhibitors of T-cell-mediated antitumoral immunity. We recently reported that B7-H1 expression by carcinomas of the kidney and bladder portends aggressive disease and diminished survival. The expression of these proteins in prostate cancer, however, has not been investigated. We evaluated B7-H3 and B7-H1 protein expression in the pathologic specimens of 338 men treated for clinically localized prostate cancer between 1995 and 1998 with radical retropubic prostatectomy. Expression levels of B7-H3 in prostate cancer were correlated with pathologic indicators of aggressive cancer as well as clinical outcome. We report that B7-H3 is uniformly and aberrantly expressed by adenocarcinomas of the prostate, high-grade prostatic intraepithelial neoplasia, and four prostate cancer cell lines, whereas B7-H1 is rarely expressed. B7-H3 is expressed by benign prostatic epithelia, although at a more reduced level relative to neoplastic tissue. Increasing levels of B7-H3 intensity correlate with worsening clinicopathologic features of prostate cancer. Marked B7-H3 intensity, present in 67 (19.8%) specimens, confers a >4-fold increased riskof cancer progression after surgery (riskratio , 4.42; P < 0.001). A survey of normal tissues revealed that B7-H3 is expressed within the liver, urothelium, and fetal kidney. In summary, B7-H3 is aberrantly expressed in all prostate cancers and represents an independent predictor of cancer progression following surgery. Moreover, B7-H3 encompasses a novel diagnostic and potential therapeutic target for the clinical management of prostate cancer and, perhaps, other malignancies as well.

AB - B7 coregulatory ligands can be aberrantly expressed in human disease. In the context of cancer, these ligands may act as antigen-specific inhibitors of T-cell-mediated antitumoral immunity. We recently reported that B7-H1 expression by carcinomas of the kidney and bladder portends aggressive disease and diminished survival. The expression of these proteins in prostate cancer, however, has not been investigated. We evaluated B7-H3 and B7-H1 protein expression in the pathologic specimens of 338 men treated for clinically localized prostate cancer between 1995 and 1998 with radical retropubic prostatectomy. Expression levels of B7-H3 in prostate cancer were correlated with pathologic indicators of aggressive cancer as well as clinical outcome. We report that B7-H3 is uniformly and aberrantly expressed by adenocarcinomas of the prostate, high-grade prostatic intraepithelial neoplasia, and four prostate cancer cell lines, whereas B7-H1 is rarely expressed. B7-H3 is expressed by benign prostatic epithelia, although at a more reduced level relative to neoplastic tissue. Increasing levels of B7-H3 intensity correlate with worsening clinicopathologic features of prostate cancer. Marked B7-H3 intensity, present in 67 (19.8%) specimens, confers a >4-fold increased riskof cancer progression after surgery (riskratio , 4.42; P < 0.001). A survey of normal tissues revealed that B7-H3 is expressed within the liver, urothelium, and fetal kidney. In summary, B7-H3 is aberrantly expressed in all prostate cancers and represents an independent predictor of cancer progression following surgery. Moreover, B7-H3 encompasses a novel diagnostic and potential therapeutic target for the clinical management of prostate cancer and, perhaps, other malignancies as well.

UR - http://www.scopus.com/inward/record.url?scp=34548046956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548046956&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-1068

DO - 10.1158/0008-5472.CAN-07-1068

M3 - Article

C2 - 17686830

AN - SCOPUS:34548046956

VL - 67

SP - 7893

EP - 7900

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 16

ER -